An RNA external guide sequence ribozyme targeting human interleukin-4 receptor α mRNA

David H. Dreyfus*, Agniesczka Matczuk, Ramsay Fuleihan

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

RNA oligonucleotides termed External Guide Sequence (EGS) and RNAi have been described that target specific gene expression by site-specific cleavage of mRNA. EGS serve as an RNA catalyst or ribozyme by directing bound mRNA to the ubiquitous cellular enzyme RNAse P. We describe an EGS targeting human interleukin (IL)-4 receptor α mRNA, an important cytokine receptor in the pathogenesis of asthma and allergic disease expressed in pulmonary tissues. This EGS was designed to explore pulmonary delivery of catalytic RNA oligonucleotides as a novel therapy in asthma and other atopic diseases. Inhaled DNA oligonucleotides termed Respirable Antisense OligoNucleotide Sequences (RASONS) are selectively internalized in lung tissues in a complex with endogenous lipid surfactants present in normal lung and can alter pulmonary gene expression. Potential applications of inhaled RNA oligonucleotides in therapy of pulmonary and related systemic diseases are discussed.

Original languageEnglish (US)
Pages (from-to)1015-1027
Number of pages13
JournalInternational Immunopharmacology
Volume4
Issue number8
DOIs
StatePublished - Aug 1 2004

Fingerprint

Guide RNA
Catalytic RNA
Oligonucleotides
Lung
Messenger RNA
RNA
Asthma
Gene Expression
Cytokine Receptors
Antisense Oligonucleotides
RNA Interference
Surface-Active Agents
human IL4R protein
Lipids
DNA
Enzymes
Therapeutics

Keywords

  • Antisense DNA
  • Catalytic RNA
  • EGS
  • Human interleukin-4 receptor α mRNA
  • RASON
  • RNAi
  • RNAse P
  • Ribozyme

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

@article{440c144ffcf54873915bf1f87e38d337,
title = "An RNA external guide sequence ribozyme targeting human interleukin-4 receptor α mRNA",
abstract = "RNA oligonucleotides termed External Guide Sequence (EGS) and RNAi have been described that target specific gene expression by site-specific cleavage of mRNA. EGS serve as an RNA catalyst or ribozyme by directing bound mRNA to the ubiquitous cellular enzyme RNAse P. We describe an EGS targeting human interleukin (IL)-4 receptor α mRNA, an important cytokine receptor in the pathogenesis of asthma and allergic disease expressed in pulmonary tissues. This EGS was designed to explore pulmonary delivery of catalytic RNA oligonucleotides as a novel therapy in asthma and other atopic diseases. Inhaled DNA oligonucleotides termed Respirable Antisense OligoNucleotide Sequences (RASONS) are selectively internalized in lung tissues in a complex with endogenous lipid surfactants present in normal lung and can alter pulmonary gene expression. Potential applications of inhaled RNA oligonucleotides in therapy of pulmonary and related systemic diseases are discussed.",
keywords = "Antisense DNA, Catalytic RNA, EGS, Human interleukin-4 receptor α mRNA, RASON, RNAi, RNAse P, Ribozyme",
author = "Dreyfus, {David H.} and Agniesczka Matczuk and Ramsay Fuleihan",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.intimp.2004.03.012",
language = "English (US)",
volume = "4",
pages = "1015--1027",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "8",

}

An RNA external guide sequence ribozyme targeting human interleukin-4 receptor α mRNA. / Dreyfus, David H.; Matczuk, Agniesczka; Fuleihan, Ramsay.

In: International Immunopharmacology, Vol. 4, No. 8, 01.08.2004, p. 1015-1027.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An RNA external guide sequence ribozyme targeting human interleukin-4 receptor α mRNA

AU - Dreyfus, David H.

AU - Matczuk, Agniesczka

AU - Fuleihan, Ramsay

PY - 2004/8/1

Y1 - 2004/8/1

N2 - RNA oligonucleotides termed External Guide Sequence (EGS) and RNAi have been described that target specific gene expression by site-specific cleavage of mRNA. EGS serve as an RNA catalyst or ribozyme by directing bound mRNA to the ubiquitous cellular enzyme RNAse P. We describe an EGS targeting human interleukin (IL)-4 receptor α mRNA, an important cytokine receptor in the pathogenesis of asthma and allergic disease expressed in pulmonary tissues. This EGS was designed to explore pulmonary delivery of catalytic RNA oligonucleotides as a novel therapy in asthma and other atopic diseases. Inhaled DNA oligonucleotides termed Respirable Antisense OligoNucleotide Sequences (RASONS) are selectively internalized in lung tissues in a complex with endogenous lipid surfactants present in normal lung and can alter pulmonary gene expression. Potential applications of inhaled RNA oligonucleotides in therapy of pulmonary and related systemic diseases are discussed.

AB - RNA oligonucleotides termed External Guide Sequence (EGS) and RNAi have been described that target specific gene expression by site-specific cleavage of mRNA. EGS serve as an RNA catalyst or ribozyme by directing bound mRNA to the ubiquitous cellular enzyme RNAse P. We describe an EGS targeting human interleukin (IL)-4 receptor α mRNA, an important cytokine receptor in the pathogenesis of asthma and allergic disease expressed in pulmonary tissues. This EGS was designed to explore pulmonary delivery of catalytic RNA oligonucleotides as a novel therapy in asthma and other atopic diseases. Inhaled DNA oligonucleotides termed Respirable Antisense OligoNucleotide Sequences (RASONS) are selectively internalized in lung tissues in a complex with endogenous lipid surfactants present in normal lung and can alter pulmonary gene expression. Potential applications of inhaled RNA oligonucleotides in therapy of pulmonary and related systemic diseases are discussed.

KW - Antisense DNA

KW - Catalytic RNA

KW - EGS

KW - Human interleukin-4 receptor α mRNA

KW - RASON

KW - RNAi

KW - RNAse P

KW - Ribozyme

UR - http://www.scopus.com/inward/record.url?scp=3042518901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042518901&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2004.03.012

DO - 10.1016/j.intimp.2004.03.012

M3 - Article

VL - 4

SP - 1015

EP - 1027

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 8

ER -